The company expects the fund to have a market capitalization of at least $5 billion after the share offering, which will be priced at $25 a share.

New York hedge fund manager Ackman, famed for aggressive moves including a $1 billion bet against US nutrition firm Herbalife, is currently engaged in a battle to broker a sale of Botox maker Allergan (>> Allergan, Inc.) to Valeant Pharmaceuticals (>> Valeant Pharmaceuticals Intl Inc).

Pershing Square Holdings said it had already received commitments worth $1.5 billion from 30 cornerstone investors. It currently has more than 300 investors.

The fund is run by Pershing Square Capital Management, a North America-focused equities investment manager founded by Ackman in 2003 which had $14.1 billion in assets under management at the end of June.

Reuters reported earlier this month that UBS (>> UBS AG) and Deutsche Bank (>> Deutsche Bank AG) were to run the listing. Credit Suisse (>> Credit Suisse Group AG) is acting as joint bookrunner, the firm said.

Pershing Square Holdings gained 31.2 percent during the first eight months of 2014, according to an investor with the fund, making it one of the industry's best performing funds of the year. It expects to be admitted for trading on Oct. 13.

(Reporting by Thomas Escritt and Freya Berry; editing by Jason Neely and Susan Thomas)